Advances in Estrogen Receptor Signaling: Potential Implications for Women's Health
Washington Convention Center, Room 140B
9:30 am – 12:00 noon
Sponsored by the Divisions for Cardiovascular Pharmacology; Integrative Systems ,Translational & Clinical Pharmacology; and the Committee on Women in Pharmacology
Chairs: A. Cignarella, Univ. of Padua, Italy, R.D.
Feldman, Univ. of Western Ontario, Canada, and V.M.Miller, Mayo Clinic
Coll. of Med.
Vascular
actions of estrogens-functional implications
Sue P. Duckles, Univ of California - Irvine
College of Medicine
Adipose
tissue biology and estrogen metabolism
Mario Kratz, Fred Hutchinson Cancer Research Ctr
Selective
estrogen receptor isoform agonists improve vascular function and metabolic
control: the need to look beyond hormones
Andrea
Cignarella, Univ
of Padua , Italy
Choreographing
the rapid vascular effects of steroids: Sorting out the partners and the steps
Ross Feldman, The Univ of Western
Ontario
Rapid
steroid effects in hypertension: role of GPR30
L.M. Fredrick
Leeb-Lundberg, Lund
Univ, Sweden
Role of Neuroinflammation in Psychiatric Disease
Washington Convention Center, Room 140A
9:30 am – 12:00 noon
Sponsored by the Divisions for Neuropharmacology; Behavioral Pharmacology; Drug Discovery, Development & Regulatory Affairs; Drug Metabolism; and Integrative Systems,Translational & Clinical Pharmacology
Chair: J.E. Clark,
Drexel Univ.
Psychoneuroimmunology: Inter-relationships between behavior and immunity
Michael Irwin, UCLA
Schizophrenia and major depression as inflammatory disorders
Aye-Mu Myint, Ludwig-Maximilians-Universitat
Cytokines sing the blues: The role of cytokines in the pathophysiology of depression
Andrew Miller, Emory Univ
Molecular mechanisms underlying the effects of chronic inflammation on depressive-like behaviors
Robert Dantzer, Univ of Illinois at Urbana-Champaign
Too Much or Too Little: Behavioral Models and Pharmacotherapies for Eating Disorders
Washington Convention Center, Room 143A/B
9:30 am – 12:00 noon
Sponsored
by the Divisions for Behavioral Pharmacology; Integrative Systems,
Translational & Clinical Pharmacology; and Neuropharmacology
Chair: M.L. Banks, Virginia Commonwealth Univ.
Pharmacotherapies
for eating disorders: A clinical perspective
Anna I. Guerdjikova, Lindner Center of Hope
Effects
of neurochemicals and drugs in altering internal states associated with acute
food deprivation
David Jewett, Univ of Wisconsin-Eau Claire
Opioid
and cannabinoid involvement in dietary-induced binge eating in rodents
Nicholas Bello, Rutgers Univ. Sch. of Envrn. and Biol. Sci.
But
is it addiction? Neurobiology and treatment of binge eating
Rebecca Corwin, Pennsylvania State Univ. College of Health and Human Develop.
Human
and non-human primate laboratory models
Richard Foltin, New York State Psychiatric Institute
Molecular Pharmacology Division Postdoctoral Award Finalists
Washington Convention Center, Room 143C
9:30 am – 12:00 noon
Keynote Lecture
Molecular pharmacology and cAMP: A marriage that has lasted for >50 years!
Paul Insel, Univ. of California San Diego
Postdoctoral Award Finalists
Lipopolysaccharide enhances TGF ß1 induction of PDGFpB in bile duct epithelial cells: Role of NF-kappaB
K. M. Kassell, Univ of Kansas Medical Center
Gαi binding sites on Calnuc and NUCB2 define a new family of structurally-related Gα regulatory motifs
M. Carcia-Marcos, Univ of California, San Diego
Targeting degradation pathways of RGS2 for novel cardiovascular therapeutics
B. Sjogren, Univ of Michigan
Promise and Partnership: FDA's Critical Path Initiative and its Intersection with Pharmacology
Washington Convention Center, Room 141
9:30 am - 12:00 noon
Sponsored by the Public Affairs Committee and the Division for Drug Discovery, Development and Regulatory Affairs
Chair: M.F. Jarvis, Abbott Laboratories
How pharmacology and
toxicology can help meet the demands of FDA’s expanding scientific portfolio
Vicki Seyfert-Margolis, Food and Drug
Administration
Need for improved clinical
trial design and improved standardization of clinical trial data to improve
public health measures
Robert Temple, Food and Drug Administration
Application of advanced
imaging technologies in drug development and clinical trial design
Richard Hargreaves, Merck
Bioinformatics and
pharmacoepidemiology: making sense of data.
Darrell Abernathy, Food and Drug
Administration
Progress in biomarkers and
translational strategies for drug development
Janet Woodcock, Food and Drug Administration
Systems biology and drug
development
Jeremy Berg, NIGMS, NIH